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ABSTRACT
Background: HIV rapid tests (RT) are a quick and non-technically demanding means 
to perform HIV voluntary counselling and testing (VCT) but understanding their 
limitations is vital to delivering quality VCT. 
Objective: To determine the sensitivity and specificity of HIV rapid tests used for 
research and voluntary counselling and testing at four sites in East Africa.
Design: Cross-sectional study.
Setting: Masaka District, Uganda; a sugar plantation in Kakira, Uganda; Coastal 
Villages in the Kilifi District of Kenya; and the Urban slum of Kangemi located  West 
of Nairobi, Kenya.
Subjects: Six thousands two hundred and fifty five consenting volunteers were enrolled 
into the study, and 675 prevalent HIV infections were identified.
Results: The RT sensitivity tended to be high for all assays at all sites (97.63-100%) with 
the exception of the Uni-Gold assay (90.24% in Kangemi, 96.58% in Kilifi). Twenty 
four RT results were recorded as ‘weak positives’, 22 (92%) of which were negative 
by ELISA. There was a high rate of RT false positives in Uganda (positive predictive 
values ranging from 45.70% to 86.62%).
Conclusions: The sensitivity and specificity of the RT varied significantly across sites. 
The rate of RT misclassification in Uganda suggests that a multiple test algorithm may 
be preferable to a single test as screener for HIV VCT.
INTRODUCTION
Traditional methods of HIV testing such as enzyme-
linked immunosorbent assays (ELISAs), and Western 
blots, which are currently used as the standard 
testing methods in the developed world, are often 
unavailable for resource-limited settings due to cost, 
turn around time to results, and technical limitations 
(1, 2). The use of rapid, less technically demanding 
tests to diagnose HIV infection has improved uptake 
of voluntary counselling and testing and facilitated 
HIV surveillance worldwide. Previous studies of 
HIV rapid tests (RT) have shown a similar sensitivity 
and specificity to traditional diagnostic methods 
(2-7). In this study, we tested a two assay HIV rapid 
algorithm, in four sites in Uganda and Kenya, to 
assess its reliability and validity in identifying 
HIV infection in individuals accessing voluntary 
counselling and testing (VCT) as part of HIV vaccine 
feasibility study.
MATERIALS AND METHODS
Study subjects: Male and female volunteers aged 
between 18 and 60 years willing to receive VCT 
for HIV and who provided informed consent to 
participate in an HIV vaccine feasibility study. The 
study involved a single visit to one of four sites: 
Rural villages in Masaka District, Uganda; a sugar 
plantation in Kakira, Uganda; Coastal Villages in 
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the Kilifi District of Kenya; and the Urban slum of 
Kangemi located west of Nairobi, Kenya. This study 
was reviewed and approved by National Institutional 
Review Boards at each site.
Rapid tests: The Determine (Abbott Laboratories, 
Japan); Uni-Gold (Trinity Biotech, Ireland); and 
Capillus (Trinity Biotech) rapid test kits were used. 
Rapid test (RT) kits were used according to the 
manufacturer’s instructions with one addition. When 
the Uni-Gold or Determine RT showed the patient test 
bar as present but fainter than the control bar, or if 
the Capillus assay showed signs of weak coagulation 
(there is no internal control for the Capillus rapid 
test), this was recorded as a “weak positive”. As 
per the manufacturer’s instructions, weak positives 
are considered a positive result for the purposes of 
this report; however, all weak positive results were 
confirmed by ELISA.
HIV testing algorithm: The HIV testing algorithm by 
site is shown in Figure I. Samples with discrepant 
RT results were subjected to confirmation by one or 
two ELISAs (Vironostika Uniform II, BioMerieux, 
Netherlands; and/or Murex HIV 1.2.0, Murex 
Biotech Ltd., UK), with Western blots (Genetic 
Systems, BioRad Laboratories) used to resolve 
any discrepancies in ELISA results for Masaka. In 
Kilifi, a third rapid test was used as a tiebreaker 
for discrepant RT results (lnstaScreen, GAIFAR) 
and ELISAs were not used. All specimens from 
volunteers diagnosed as HIV -infected were 
sent to an independent laboratory (Contract 
Laboratory Services, Johannesburg, South Africa) 
for confirmation of HIV antibody status by a third 
ELISA (Axsym HIV 1 and 2, Abbott Laboratories). 
In Masaka, all specimens found to be HIV antibody 
negative by RT were confirmed by dual ELISAs 
(Figure I), at the other sites, no further testing was 
done on volunteers diagnosed as HIV-uninfected.
Figure 1 
























Positives sent to independent laboratories for HIV antibody status confirmation (Axsym HIV 1and 2)
*Western Blot was used to resolve discrepant results in Masaka if ELISA results were discordant
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Assay accuracy: For each rapid test, the sensitivity, 
specificity, positive and negative predictive values, 
and overall accuracy were calculated. Sensitivity 
(the proportion of infected volunteers with antibody 
positive results) and specificity (the proportion of 
uninfected volunteers with antibody negative results) 
are shown as percentages. The Positive Predictive 
Value (PPV), the proportion of people with a positive 
RT or RT algorithm result who have antibody-positive 
HIV infection and Negative Predictive Value (NPV), 
the proportion of people with a negative RT or RT 
algorithm result who do not have antibody-positive 
HIV infection, shown as percentages, were calculated 
according to Bayes’ theorem(8). The overall accuracy 
was calculated as the percentage of correct test results: 
(a+d)/(a+b+c+d), where a=true positives, b=false 
positives, c=false negatives, and d=true negatives.
RESULTS
A total of 6,255 volunteers were enrolled into the 
study, and 675 prevalent infections were identified. 
For all sites the sensitivity and specificity of each 
rapid test varied (Table I).
Table 1
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of HIV 
rapid tests used at two sites in Kenya and two in Uganda
 HIV Assay(s) Sensitivity Specificity PPV NPV Accuracy
Site Prevalence  (%) (%) 0/0 (%) (%)
Kangemi, 164/1000 Determine 98,78 99,76 97.38 99.89 99.60
Kenya (16.4%) UniGold 90.24 99.64 95.77 99.13 98.10
Kilifi, 146/1769 Determine 100 99.59 95.42 100 99.60
Kenya (8.3%) UniGold 96.58 99.83 98.60 99.69 99,60
Kakira, 196/2004 Determine 98.98 95.35 65.71 99.90 95.71
Uganda (9.8%) Capillus 99.49 98.62 86.62 99.95 98.70
Masaka, 169/1482 Determine 97.63 89.57 45.70 99.76 90.49
Uganda (11.4%) 
The UniGold RT recorded the lowest sensitivities, at 
90.24% in Kangemi, and 96.58% in Kilifi, however 
the UniGold specificity was high (99.64% and 
99.83% respectively). The Determine RT, used at 
all sites, had a high sensitivity (>97%), but the high 
rate of false positives (FP) recorded in Uganda 
resulted in low PPVs. The Capillus RT was used 
only in Kakira, performing with high sensitivity 
(99.49%), however the number of FP observed 
with this assay resulted in a lower PPV (86.62%). 
Due to the low number of FP in Kenya, the PPV 
of both rapid tests were high.
 Twenty four positive results were recorded 
as weak positive (0 in Kangemi, 16 in Kakira, 
one  in Masaka, and seven in Kilifi), 22 of which 
(92%) were antibody negative by ELISA (i.e., FP). 
Of 131 volunteers with discrepant RT results (one 
test positive, one test negative), twenty six (19.8%) 
volunteers were confirmed as HIV-infected by a 
third ELISA test. Specimens were not available for 
assessing viral load. This varied significantly by site, 
three cases out of 102 (2.9%) in Kakira, 5/8 (62.5%) in 
Kilifi, and 18/21 (85.7%) in Kangemi (Masaka used 
only one RT).
DISCUSSION
Overall, no rapid test performed well enough 
to recommend its use as a single diagnostic 
measurement. RT discrepant results were  uncommon, 
and at Kangemi and Kilifi a high proportion of 
volunteers with these results were HIV -infected. 
Recent work at a STD clinic in Malawi reported that 
seven out of twenty one (33%) of volunteers with PCR-
confirmed acute HIV infection were RT discrepant 
(9). While only one Ugandan site used two RT, the 
majority of the HIV discrepant results came from this 
site, and few (2.9%) were truly HIV-infected. Although 
we found that the Determine assay performed with 
a high sensitivity at all four sites, its specificity at the 
Ugandan sites was lower, and the high rate of false 
positives resulted in low PPVs. Although the assay 
package inserts for all three RT evaluated in this report 
do not mention weak positive results (the results 
are either positive or negative), the interpretation of 
these assays can be subjective, especially the Capillus 
assay which does not include an internal control. We 
observed 2% weak positive results, however more 
than 90% of these were FP. A similar experience has 
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been reported by investigators in Rakai, Uganda (10). 
Although the investigators in this study reported a 
significant improvement in PPV by censoring their 
weak positive results, we found fewer weak positive 
results, and censoring them had negligible effects on 
the assay PPV (data not shown). The sensitivity and 
specificity of an HIV RT may vary depending on the 
local HIV strain and the population being tested (2, 
11, 12). Problems with FP RT results have recently 
been reported in the US (13).
 At three of the four sites, we did not confirm 
the antibody status of volunteers who were HIV 
negative by two rapid tests. While misdiagnosing 
infections as uninfected would affect both sensitivity 
and specificity, it is likely that these misclassifications 
are few; only five of 1,181 (0.4%).  Determine-negative 
results were confirmed as antibody-positive HIV 
infection in Masaka. The only site to confirm antibody 
status among all volunteers, Masaka, recorded the 
lowest sensitivity and specificity for the Determine 
assay. Originally, Masaka had begun this study with 
a two-RT algorithm, but due to a high rate of false 
positives noted early in the study we decided to switch 
to ELISA for confirmation of HIV status for all study 
volunteers. We did not have sufficient specimens to 
test for the presence of virus and it is possible that 
discrepant RT results confirmed as HIV uninfected 
by ELISA may have instead been due to early HIV 
infection prior to full seroconversion. A review 
of assay and laboratory procedures indicates that 
technician error or assay malfunction was unlikely, 
and it remains unclear what may have resulted in this 
poor specificity. Were we to use the most sensitive RT 
(Determine) as a screener to prompt confirmation by 
a second test, we would have missed 5/169 (3.0%) 
infections in Masaka, and at least 2/164 (1.2%) in 
Kangemi, 2/196 (1.0%) in Kakira and 0/146 (0%) in 
Kilifi. While a two-test algorithm is more expensive, 
the improvements in sensitivity, specificity, and 
predictive value are significant on the scale of national 
VCT programmes. With VCT uptake at government 
test sites nearly 800,000 in Kenya in 2006 (14) and 
1.2 million in Uganda in 2004 (15), use of a single 
test algorithm could misdiagnose thousands of HIV 
infected individuals. The addition of a second test at 
a cost of approximately 1 US$ per test would improve 
sensitivity at a cost of a few hundred dollars per HIV 
infected individual identified, making this algorithm 
improvement comparably cost-effective relative to 
other methods (16).
 Our results suggest that a two-test algorithm 
can be utilised to rapidly identify HIV-infected 
individuals in East Africa, providing cost-effective 
improved diagnostic ability over a single RT used as 
a screening test. However, our results suggest that 
RT alone are not always effective; through RT testing 
prior to widespread use, and additional confirmatory 
diagnostic measures are highly recommended. As 
HIV continues to spread and access to anti-retroviral 
therapy expands throughout the developing world 
the ability to accurately and rapidly identify HIV-
infected individuals will play a crucial role in 
preventing further transmission and providing life 
saving care and treatment (11,12).
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